Clinical Trials Logo

Localized Cancer clinical trials

View clinical trials related to Localized Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05510895 Recruiting - Colorectal Cancer Clinical Trials

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

NeoBRAF
Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

AIO-KRK-0420 NeoBRAF is a single arm, multicenter, phase II trial with neoadjuvant encorafenib, binimetinib and cetuximab for patients with BRAF V600E mutated/pMMR localized colorectal cancer.

NCT ID: NCT05406713 Recruiting - Clinical trials for Urothelial Carcinoma

Pembrolizumab in Muscle-invasive Bladder Cancer

Start date: July 13, 2022
Phase: Phase 2
Study type: Interventional

Subjects with cT2-T3N0M0 urothelial cancer of the bladder will be enrolled. After completing two cycles of pembrolizumab, subjects will undergo a restaging MRI of the abdomen and pelvis with a standard acquisition protocol (as outlined in the protocol) as well as CT chest. A CT of the abdomen and pelvis may be performed if there are contraindications to MRI. Patients will also undergo a restaging cystoscopy and biopsies/TURBT as outlined in the protocol. Patients achieving a clinical complete response to treatment (defined in the protocol) will proceed with "maintenance" single agent pembrolizumab followed by surveillance. All other patients will proceed with standard of care local therapy as per their treating physicians followed by "adjuvant" pembrolizumab.